the role of triplet therapy in men with metastatic castration sensitive prostate cancer
Published 1 year ago • 505 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
4:05
evaluating triplet therapy in metastatic hormone sensitive prostate cancer
-
0:47
systemic triple therapy in metastatic hormone-sensitive prostate cancer
-
2:05
abiraterone in metastatic castration-sensitive prostate cancer
-
3:06
treatment intensification in metastatic castration-sensitive prostate cancer
-
2:27
triplet therapy for metastatic hormone-sensitive prostate cancer
-
1:33
the role of radium 223 in metastatic castration resistant prostate cancer
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
5:06
va starport prostate cancer clinical trial
-
0:52
dr. lawrence karsh on treatment sequencing in metastatic castration-resistant prostate cancer
-
0:45
treatment sequencing for metastatic castration-resistant prostate cancer
-
1:33
fih study of arv-110 in metastatic castrate-resistant prostate cancer
-
4:22
fatigue in men with castration resistant prostate cancer treated with enzalutamide
-
3:56
about metastatic castrate-resistant prostate cancer
-
5:46
metastatic castration-resistant prostate cancer – new learnings and perspectives
-
0:58
biomarkers associated with parpi response in patients with castration-resistant prostate cancer
-
3:12
is the triplet regimen standard of care for metastatic castrate-sensitive prostate cancer?
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
5:27
peace-1: 8-month psa determines outcomes in men with mcspc
-
2:41
recent developments in treatment options for castration-sensitive metastatic prostate cancer